货号:A240973
同义名:
Carprodyl; NSC 297935
Carprofen是一种非甾体抗炎剂,通过抑制 COX-2(IC50 = 3.9 μM)和 FAAH(IC50 = 78.6 μM)表现出抗炎和止痛作用,对 COX-1 活性抑制较弱。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | COX ↓ ↑ | COX-1 ↓ ↑ | COX-2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piroxicam | ✔ | 98% | |||||||||||||||||
| Salicylic acid | ✔ | 98% | |||||||||||||||||
| Phenacetin | ✔ | 98% | |||||||||||||||||
| Etodolac | ✔ | 99% | |||||||||||||||||
| Flunixin meglumine | ✔ | 98% | |||||||||||||||||
| Ibuprofen L-lysine | ✔ | 98% | |||||||||||||||||
| Nabumetone | ✔ | 98% | |||||||||||||||||
| Acemetacin | ✔ | 98% | |||||||||||||||||
| Diflunisal | ✔ | 98% | |||||||||||||||||
| Pranoprofen | ✔ | 98% | |||||||||||||||||
| Ampiroxicam | ✔ | 98% | |||||||||||||||||
| Meloxicam | ✔ | 98% | |||||||||||||||||
| Sulindac | ✔ | 98% | |||||||||||||||||
| Ketoprofen | ✔ | 98% | |||||||||||||||||
| Mefenamic Acid | ✔ | 95% | |||||||||||||||||
| Bromfenac sodium | ✔ | 98% | |||||||||||||||||
| Oxaprozin | ✔ | 99% | |||||||||||||||||
| Aspirin | ✔ | 99% | |||||||||||||||||
| Nepafenac | ✔ | 98% | |||||||||||||||||
| Zaltoprofen | ✔ | 99% | |||||||||||||||||
| Salicin | ✔ | 98% | |||||||||||||||||
| Suprofen | ✔ | 99%+ | |||||||||||||||||
| Xanthohumol | ✔ | 99% | |||||||||||||||||
| Parecoxib | ✔ | 98% | |||||||||||||||||
| Tolfenamic Acid |
+++
COX-2, IC50: 0.2 μM |
98% | |||||||||||||||||
| Etoricoxib | ✔ | 99% | |||||||||||||||||
| Niflumic Acid | ✔ | 98% | |||||||||||||||||
| Valdecoxib |
++++
COX-2, IC50: 5 nM |
99+% | |||||||||||||||||
| Ibuprofen |
+
COX-1, IC50: 13 μM |
+
COX-2, IC50: 370 μM |
98% | ||||||||||||||||
| Indomethacin |
++
COX1, IC50: 0.28 μM |
+
COX-2, IC50: 14 μM |
97% | ||||||||||||||||
| Lornoxicam |
++++
COX-1, IC50: 5 nM |
++++
COX-2, IC50: 8 nM |
98% | ||||||||||||||||
| Meclofenamic acid sodium |
++++
COX-1, IC50: 40 nM |
+++
COX-2, IC50: 50 nM |
99% | ||||||||||||||||
| Asaraldehyde | ✔ | 98% | |||||||||||||||||
| Naproxen |
+
COX-1, IC50: 8.7 μM |
+
COX-2, IC50: 5.2 μM |
98% | ||||||||||||||||
| Diclofenac Sodium Salt |
+++
COX-1, IC50: 60 nM |
+++
COX-2, IC50: 200 nM |
98% | ||||||||||||||||
| NS-398 |
++
COX-2, IC50: 3.8 μM |
95% | |||||||||||||||||
| Amfenac Sodium Hydrate |
++
COX-1, IC50: 250 nM |
+++
COX-2, IC50: 150 nM |
98%+ | ||||||||||||||||
| Nimesulide |
+
COX-2, IC50: 26 μM |
98% | |||||||||||||||||
| Lumiracoxib |
++
COX-1, Ki: 3 μM |
+++
COX-2, Ki: 60 nM |
98% | ||||||||||||||||
| Rutaecarpine | ✔ | 95% | |||||||||||||||||
| Celecoxib |
++++
COX-2, IC50: 40 nM |
98% | |||||||||||||||||
| Carprofen |
++++
canine COX2, IC50: 30 nM |
98% | |||||||||||||||||
| Ketorolac |
++
COX-1 (human), IC50: 1.23 μM |
++
COX-2 (human), IC50: 3.50 μM |
98% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively[3]. Carprofen (10 µg/mL) shows cytoprotective effects in CCL (cranial) and CaCL (caudal) cells and decreases apoptosis of both cells. Carprofen (10 μg/mL) had the greatest cytoprotective effects for CCL and CaCL cells[4]. Carprofen acts in vivo on target tissues as COX-1-sparing drugs by sparing gastric PGE1 and PGE2 synthesis and production of TXB2 (thromboxane B2) by platelets[5]. The administration of maropitant alone and carprofen alone produced clinically significant sparing effects on the sevoflurane MAC-BAR (minimum alveolar concentration for blunting adrenergic response) in dogs. However, the combination of maropitant and carprofen did not produce any additive effect on the sevoflurane MAC-BAR reduction[6]. |
| Concentration | Treated Time | Description | References | |
| T24 bladder cancer cells | 40-100 μM | 48 h | Induced p75NTR expression and inhibited cell survival | Mol Cancer Ther. 2008 Nov;7(11):3539-45 |
| DU-145 prostate cancer cells | 40-100 μM | 48 h | Induced p75NTR expression and inhibited cell survival, inducing apoptosis via the p38 MAPK pathway | Mol Cancer Ther. 2008 Nov;7(11):3539-45 |
| PC-3 prostate cancer cells | 40-100 μM | 48 h | Induced p75NTR expression and inhibited cell survival, inducing apoptosis via the p38 MAPK pathway | Mol Cancer Ther. 2008 Nov;7(11):3539-45 |
| H4 neuroglioma cells | 100 μM | overnight | Evaluate the effects of NSAIDs on Aβ42 secretion. Carprofen was the most potent compound, reducing Aβ42 by more than 90%. | Neurobiol Dis. 2010 Sep;39(3):449-56 |
| Mycobacterium tuberculosis H37Rv | 400 mg/L | 4 h | Assess the effect of carprofen on gene expression in Mycobacterium tuberculosis | J Antimicrob Chemother. 2020 Nov 1;75(11):3194-3201 |
| Mycobacterium smegmatis | 62.5 mg/L | 5 days | Evaluate the effect of carprofen on extracellular polymeric substances (EPS) in Mycobacterium smegmatis biofilms | J Antimicrob Chemother. 2020 Nov 1;75(11):3194-3201 |
| Mycobacterium smegmatis | 250 mg/L | 5 days | Assess the inhibitory effect of carprofen on biofilm formation in Mycobacterium smegmatis | J Antimicrob Chemother. 2020 Nov 1;75(11):3194-3201 |
| Mycobacterium smegmatis | 62.5 mg/L | 60 min | Evaluate the inhibitory effect of carprofen on efflux pumps in Mycobacterium smegmatis | J Antimicrob Chemother. 2020 Nov 1;75(11):3194-3201 |
| Mycobacterium smegmatis | 250 mg/L | 24 h | Determine the minimum inhibitory concentration (MIC) of carprofen against Mycobacterium smegmatis | J Antimicrob Chemother. 2020 Nov 1;75(11):3194-3201 |
| Administration | Dosage | Frequency | Description | References | ||
| Transgenic mice | T7A6 mice | Food | 10 mg/kg | Daily for 6 months | Evaluate the effect of Carprofen on Aβ42 levels in muscle. Carprofen had no significant effect on Aβ42 levels in muscle. | Neurobiol Dis. 2010 Sep;39(3):449-56 |
| Mice | Inflammatory pain model (CFA-induced) | Intraperitoneal injection | 5 mg/kg | Starting 1 hour prior to testing on days 2, 4 and 5 following saline/CFA injection. | To evaluate the effect of carprofen on voluntary gait changes in CFA-induced inflammatory pain model. Results showed that carprofen did not significantly reverse CFA-induced gait changes but completely attenuated CFA-induced heat and mechanical hypersensitivity. | Neuropharmacology. 2018 Mar 1;130:18-29 |
| Rats | Excisional wound pain model | Subcutaneous injection | 5 mg/kg | Single dose, evaluated at 1, 4, and 24 hours post-administration | To evaluate the effect of Carprofen on pain responses to thermal and mechanical stimulation in an excisional wound pain model. Results showed that Carprofen increased the withdrawal time to thermal stimulation at 1 and 4 hours post-administration but had no significant effect on mechanical withdrawal thresholds. | Korean J Pain. 2021 Apr 1;34(2):165-175 |
| Canine | Healthy dogs | Oral | 4.4 mg/kg | Single dose, observed for 6 hours | Evaluated the effect of Carprofen on growth factor and cytokine release, showing increased TGF-β1 concentrations at 6 h and significantly decreased IL-10 concentrations | Gels. 2024 Jun 12;10(6):396 |
| Mice | STR/Ort mice spontaneous osteoarthritis model | Intraperitoneal injection | 5 mg/kg | 3 consecutive days | To evaluate the effect of carprofen on osteoarthritis-related pain relief. Results showed that carprofen treatment did not modify any gait measurements or treadmill noncompliance, suggesting that gait changes in STR/Ort mice were not due to pain. | Arthritis Rheumatol. 2014 Jul;66(7):1832-42 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.65mL 0.73mL 0.37mL |
18.27mL 3.65mL 1.83mL |
36.53mL 7.31mL 3.65mL |
|
| CAS号 | 53716-49-7 |
| 分子式 | C15H12ClNO2 |
| 分子量 | 273.71 |
| SMILES Code | CC(C1=CC(NC2=C3C=C(Cl)C=C2)=C3C=C1)C(O)=O |
| MDL No. | MFCD00079028 |
| 别名 | Carprodyl; NSC 297935; Rovera; Imafen; Novox; quellin; C 5720; Ro 20-5720; Ridamyl; Rimadyl; Imadyl |
| 运输 | 蓝冰 |
| InChI Key | PUXBGTOOZJQSKH-UHFFFAOYSA-N |
| Pubchem ID | 2581 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(383.61 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1